Oppenheimer analyst Kevin DeGeeter said Novavax addressed two of what he sees as the three "big unknowns" that any potential acquirer will likely want clarity on with its disclosures this week that it sold its two manufacturing facilities and the FDA is supportive of an accelerated approval pathway for the company's flu vaccine, NanoFlu. The thid "big unknown," namely regulatory clarity on a path for ResVax in Europe, should be clarified in Q4, said DeGeeter, who noted that his Outperform rating on the stock is based in part on the company's potential to restructure for a potential sale in 2020. He maintains a $25 price target on Novavax shares.